Mechanisms of adenosine-induced cytotoxicity and their clinical and physiological implications

BioFactors

Volumn 27, Issue 1-4, 2006, Pages 213-230

  Seetulsingh Goorah, Sharmila P ^a  

^a UNIVERSITY OF MAURITIUS   (Mauritius)

Author keywords

Adenosine; Clinical uses; Cytotoxicity; Extracellular ATP (ATPo); P1 receptors; P2 receptors; Pyrimidine starvation

Indexed keywords

2' DEOXYADENOSINE 3' PHOSPHATE; ADENINE; ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; ADENOSYLHOMOCYSTEINASE; ALKALINE PHOSPHATASE; CYCLIC AMP; DEOXYADENOSINE; DEOXYADENOSINE DIPHOSPHATE; DEOXYADENOSINE TRIPHOSPHATE; DNA; GUANOSINE PHOSPHATE; HISTAMINE; HYPOXANTHINE; INOSINE; INOSINE PHOSPHATE; LEUKOTRIENE DERIVATIVE; NUCLEOSIDE DERIVATIVE; OXYGEN RADICAL; PURINE; PYRIMIDINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; UNINDEXED DRUG; URIC ACID; XANTHINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 33748925074     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520270119     Document Type: Article

References (109)

1. J. Aarbakke, G. Janka-Schaub and G.B. Elion, Thiopurine biology and pharmacology, Trends in Pharmacological Sciences 18 (1997), 3-7.
2. M.P. Abbracchio, S. Ceruti, D. Barbieri, C. Franceschi, W. Malorni, L. Biondo, G. Burnstock and F. Cattabeni, A novel action for adenosine: apoptosis of astroglial cells in rat brain primary cultures, Biochemical and Biophysical Research Communications 213 (1995), 908-915.
3. 3 receptors in rat brain, Molecular Pharmacology 48 (1995), 1038-1045.
4. M.P. Abbracchio and G. Burnstock, Purinergic signalling: pathophysiological roles, Japanese Journal of Pharmacology 78 (1998), 113-145.
5. S.G. Apasov, M. Koshiba, T.M. Chused and M.V. Sitkovsky, Effects of extracellular ATP and adenosine on different thymocyte subsets, Journal of Immunology 158 (1997), 5095-5105.
6. S. Archer, P. Juranka, J.H. Ho and V. Chan, An analysis of multiple mechanisms of adenosine toxicity in Baby Hamster Kidney cells, Journal of Cell Physiology 124 (1985), 226-232.
7. A.A. Babiker, G. Ronquist, B. Nilsson and K.N. Ekdahl, Overexpression of ecto-protein kinases in prostasomes of metastatic cell origin, Prostate (2006), Abstract- Epub ahead of print.
8. A.S. Bagnara, L.E. McDonald and H.M. Slade, Deoxyadenosine toxicity in an adenosine deaminase-inhibited human CCRF-CEM T-lymphoblastoid cell line causes cell swelling, Biochimica Biophysica Acta 1180 (1992), 163-172.
9. S. Batra and I. Fadeel, Release of intracellular calcium and stimulation of cell growth by ATP and histamine in human ovarian cancer cells, Cancer Letters 77 (1994), 57-63.
10. L. Bazzichi, L. Trincavelli, A. Rossi, F. De Feo, A. Lucacchini, S. Bombardieri and C. Martini, A2B adenosine receptor activity is reduced in neutrophils from patients with systemic sclerosis Arthritis Research and Therapy 7 (2004), R189-R195.
11. P. Benveniste and A. Cohen, p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency, Proceedings of the National Academy of Science USA 92 (1995), 8373-8377.
12. C.D. Bloomfield, K.A. Foon and E.G. Levine, Leukemias, in: Medical Oncology, P. Calabresi and P.S. Schein, eds, McGraw-Hill, Inc., New York, 1993, pp. 459-492.
13. A.V. Boddy and J.R. Idle, The role of pharmacogenetics in chemotherapy: modulation of tumour response and host toxicity, Cancer Surv. 117 (1993), 79-103.
14. J.M. Boeynames and J.D. Pearson, P2 purinoceptors on vascular endothelial cells: Physiological significance and transduction mechanisms, Trends in Pharmacological Sciences 11 (1990), 34-37.
15. P. Calabresi, J. Clark, A.R. Hanauske and M.C. Wiemann, Pharmacology of antineoplastic agents, in: Medical Oncology, P. Calabresi and P.S. Schein, eds, McGraw-Hill, Inc., New York, 1993, pp. 263-287.
16. B.D. Cheson, The purine analogs - a therapeutic beauty contest, Journal of Clinical Oncology 10 (1992), 352-355.
17. A. Chinellato, E. Ragazzi, L. Pandolfo, G. Froldi, L. Caparrotta and G. Fassina, Pharmacological characterization of a new purinergic receptor site in rabbit aorta, General Pharmacology 23 (1992), 1067-1071.
18. S.C. Chow, G.E.N. Kass and S. Orrenius, Purines and their roles in apoptosis, Neuropharmacology 36 (1997), 1149-1156.
19. 2X1, in thymocyte apoptosis, Immunity 5 (1996), 275-283.
20. 2) release from activated neutrophils, Clinical Immunology and Immunopathology 42 (1987), 76-85.
21. B.N. Cronstein, R.I. Levin, M.R. Philips, R. Hirschhorn, S.B. Abramson and G. Weisman, Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors, Journal of Immunology 148 (1992), 2201-2206.
22. B.N. Cronstein and K.A. Haines, Stimulus-response uncoupling in the neutrophil, Adenosine A2-receptor occupancy inhibits the sustained, but not the early, events of stimulus transduction in human neutrophils by a mechanism independent of actin-filament formation, Biochemical Journal 281 (1992), 631-635.
23. R.A. Cunha and A.M. Sebastiao, Extracellular metabolism of adenine nucleotides and adenosine in the innervated skeletal muscle of the frog, European Journal of Pharmacology 197 (1991), 83-92.
24. H.H. Dalziel and D.P. Westfall, Receptors for adenine nucleotides and nucleosides: subclassification, distribution and molecular characterisation, Pharmacological Reviews 46 (1994), 449-466.
25. D.D. Dawicki, D. Chatterjee, J. Wyche and S. Rounds, Extracellular ATP and adenosine cause apoptosis of pulmonary artery endothelial cells, American Journal of Physiology 273 (1997), L485-L494.
26. E.G. Delicado, T. Casillas, R.P. Sen and M.T. Miras-Portugal, Evidence that adenine nucleotides modulate nucleoside-transporter function, European Journal of Biochemistry 225 (1994), 355-362.
27. G. Dent, M.A. Giembycz, K.F. Rabe, B. Wolf, P.J. Barnes and H. Magnussen, Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase, American Journal of Respiratory Cell and Molecular Biology 10 (1994), 565-572.
28. P.C. Endresen, T.J. Eide and J. Aarbakke, Cell death initiated by 3-deazaadenosine in HL-60 cells is apoptosis and is partially inhibited by homocysteine, Biochemical Pharmacology 46 (1993), 1893-1901.
29. C.I. Ezeamuzie, Involvement of A3 receptors in the potentiation by adenosine of the inhibitory effect of theophylline on human eosinophil degranulation: possible novel mechanism of the anti-inflammatory action of theophylline, Biochemical Pharmacology 61 (2001), 1551-1559.
30. C.I. Ezeamuzie and E. Philips, Positive coupling of atypical adenosine A3 receptors on human eosinophils to adenylyl cyclase, Biochemical and Biophysical Research Communications 300 (2003), 712-718.
31. W.G. Fang, F. Pirnia, Y.J. Bang, C.E. Myers and J.B. Trepel, P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells, Journal of Clinical Investigation 89 (1992), 191-196.
32. T.C. Fisher, A.E. Milner, C.D. Gregory, A.L. Jackman, G.W. Aherne, J.A. Hartley, C. Dive and J.A. Hickman, Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways, Cancer Research 53 (1993), 3321-3326.
33. I.H. Fox and W.N. Kelley, The role of adenosine and 2′- deoxyadenosine in mammalian cells, Annual Review of Biochemistry 47 (1978), 655-686.
34. G. Frascotti, P. Coccetti, M.A. Vanoni, L. Alberghina and E. Martegani, The overexpression of the 3′ terminal region of the CDC25 gene of Saccharomyces cerevisiae causes growth inhibition and alteration of purine nucleotides, Biochimica Biophysica Acta 1089 (1991), 206-212.
35. I. Friedberg, I. Belzer, O. Oged-Plesz and D. Kuebler, Activation of cell growth inhibitor by ectoprotein kinase-mediated phosphorylation in transformed mouse fibroblasts, Journal of Biological Chemistry 270 (1995), 20560-20567.
36. M.R. Hayden and S.C. Tyagi, Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycaemia a late manifestation? The role of NOS, NO and redox stress, Cardiovascular Diabetology 2 (2003), 2, BioMed Central-Open Access.
37. T. Herdegen, P. Skene and M. Bahr, The c-Jun transcription factor-bipotential mediator of neuronal death, survival and regeneration, Trends in Neurosciences 20 (1997), 227-231.
38. D.W. Hoskin, T. Reynolds and T. Blay, 2-Chloroadenosine inhibits the MHC-unrestricted cytolytic activity of anti-CD3-activated killer cells: evidence for the involvement of a non-A1/A2 cell-surface adenosine receptor, Cellular Immunology 159 (1994), 85-93.
39. R. Hosono and S. Kuno, Mechanism of inhibition of bacterial growth by adenine, Journal of Biochemistry 75 (1974), 215-220.
40. 3 adenosine receptor-selective antagonists, Neuropharmacology 36 (1997), 157-1165.
41. K.A. Jacobson, D.K.J.E. von Lubitz, J.W. Daly and B.B. Fredholm, Adenosine receptor ligands: differences with acute versus chronic treatment, Trends in Pharmacological Sciences 17 (1996), 108-113.
42. A.C. Kay, C.J. Saven, C.J. Carrera, D.A. Carson, D. Thurston, E. Beutler and L.D. Piro, 2-chlorodeoxyadenosine treatment of low-grade lymphomas, Journal of Clinical Oncology 10 (1992), 371-377.
43. M.J. Keating, H. Kantarjian, M. Talpaz, J. Redman, C. Koller, B. Barlogie, W. Velasquez, W. Plunkett, E.J. Freireich and K.B. McCredie, Fludarabine: a new agent with major activity against chronic lymphocytic leukaemia, Blood 74 (1989), 19-25.
44. E.-I. Kodama, S. Kohgo, K. Kitano, H. Machida, H. Gatanaga, S. Shigeta, M. Matsuoka, H. Ohrui and H. Mitsuya, 2001. 4′-ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro, Antimicrobial Agents and Chemotherapy 45 (2001), 1539-1546.
45. 3 receptor agonists, Biochemical and Biophysical Research Communications 219 (1996), 904-910.
46. K. Kramer, H.O. Harrington, Q. Lu, R. Bellas, J. Newton, K.L. Sheahan and S. Rounds, Isoprenylcysteine carboxyl methyltransferase activity modulates endothelial cell apoptosis, Molecular Biology of the Cell 14 (2003), 848-857.
47. J.S. Kulkarni, D.A. Przywara, T.D. Wakade and A.R. Wakade, Adenosine induces apotosis by inhibiting mRNA and protein synthesis in chick embryonic sympathetic neurons, Neuroscience Letters 248 (1998), 187-190.
48. J.B. Kwok and M.H. Tattersall, Inhibition of 2-desamino-2-2-methyl-10- propagyl-5,8-dideazafolic acid cytotoxicity by 5,10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools, Biochemical Pharmacology 42 (1991), 507-513.
49. J.B. Kwok and M.H. Tattersall, DNA fragmentation, dATP pool elevation and potentiation of antifolate cytotoxicity in L1210 cells by hypoxanthine, British Journal of Cancer 65 (1992), 503-508.
50. C. Lee, Decrease in equilibrative uridine transport during monocytic differentiation of HL-60 leukaemia: involvement of protein kinase C, Biochemical Journal 300 (1994), 407-412.
51. +-dependent nucleoside transport system, In vivo 8 (1994), 795-802.
52. S.C. Lu, l. Alvarez, Z.-Z. Huang, L. Chen, W. An, F.J. Corrales, M.A. Avila, G. Kanel and J.M. Mato, Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation, Proceedings of the National Academy of Science USA 98 (2001), 5560-5565.
53. P. Lund, N.W. Cornell and H.A. Krebs, Effect of adenosine on the adenine nucleotide content and metabolism of hepatocytes, Biochemical Journal 152 (1975), 593-599.
54. S. Majewski, M. Skopinska, M. Blaszcyk, M. Ryba, P. Grieb, T. Chorzelski and S. Jablonska, Sytemic administration of 2-chloro-2′-deoxyadenosine (2-CdA) in patients with systemic sleroderma, Archivum Immunologiae et Therapiae Experimentalis (Warsz) 42 (1994), 33-34.
55. P.P. Major, R.P. Agarwal and D.W. Kufe, Clinical pharmacology of deoxycoformycin, Blood 58 (1981), 91-96.
56. A.P. Makrigiannis, J. Blay and D.W. Hoskin, Cyclosporin A inhibits 2-chloroadenosine-induced DNA cleavage in mouse thymocytes, International Journal of Immunopharmacology 16 (1994) 995-1001.
57. M.L. Martinez-Chantar, Spontaneous oxidative stress and liver tumours in mice lacking methionine adenosyltransferase 1A, FASEB Journal 16 (2002), 1292-1294.
58. D.I. Marquardt, H.E. Gruber and S.I. Wasserman, Adenosine release from stimulated mast cells, Proceedings of the National Academy of Science USA 81 (1984), 6192-6196.
59. R.M. Mentzer, R. Rubio and R.M. Berne, Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation, American Journal of Physiology 229 (1975), 1625-1631.
60. P. Meunier, P. Filipe, I. Emerit, J. Freitas, F. Guera Rodrigo and C. Manso, Adenosine deaminase in progressive systemic sclerosis, Acta Dermato-Venereologica 75 (1995), 297-299.
61. F.L. Meyskens and H.E. Williams, Adenosine metabolism in human erythrocytes, Biochimica Biophysica Acta 240 (1971), 170-179.
62. G.C. Mills, F.C. Schmalstieg, K.B. Trimmer, A.S. Goldman and R.M. Goldblum, Purine metabolism in adenosine deaminase deficiency, Proceedings of the National Academy of Science USA 73 (1976), 2867-2871.
63. M.T. Miras-Portugal, M. Torres, P. Rotlan and D. Aunis, Adenosine transport in bovine chromaffin cells in culture, Journal of Biological Chemistry 261 (1986), 1712-1719.
64. M. Montserrat, A. Colell, A. Morales, C. Paneda, I. Varela-Nieto, C. Garcia-Ruiz and J.C. Fernandez-Checa, Acidic sphigomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor-induced lethal hepatitis, Journal of Clinical Investigation 113 (2004), 895-904.
65. F.B. Morrone, A.P. Horn, J. Stella, F. Spiller, J.J. Sarkis, C.G. Salbego, G. Lenz and A.M. Battastini, Increased resistance of glioma cell lines to extracellular ATP cytotoxicity, Journal of Neurooncology 71 (2005), 35-40.
66. 1 adenosine receptor, Journal of Biological Chemistry 267 (1992), 10764-10770.
67. F.N. Osborne, K.K. Kalsi, C. Lawson, M. Lavitrano, M.H. Yacoub, M.L. Rose and R.T. Smolenski, Expression of human ecto-5′-nucleotidase in pig endothelium increases adenosine production and protects from NK cell-mediated lysis, American Journal of Transplantation 5 (2005), 1248-1255.
68. T.M. Palmer and G.L. Stiles, Structure-function analysis of inhibitory adenosine receptor regulation, Neuropharmacology 36 (1997), 1141-1147.
69. L.D. Piro, C.J. Carrera, E. Beutler and D.A. Carson, 2- chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukaemia, Blood 72 (1988), 1069-1073.
70. L.D. Piro, C.J. Carrera, D.A. Carson and E. Beutler, Lasting remissions in hairy-cell leukaemia induced by single infusion of 2-chlorodeoxyadenosine, New England Journal of Medicine 322 (1992), 1117-1121.
71. P.G.W. Plagemann and R.M. Wohlhueter, Permeation of nucleosides, nucleic acid bases, and nucleotides in animal cells, Current Topics in Membranes 14 (1980), 225-330.
72. G. Planet and I.H. Fox, Inhibition of phosphoribosylpyrophosphate synthesis by purine nucleosides in human erythrocytes, Journal of Biological Chemistry 251 (1976), 5839-5844.
73. W. Plunkett, S. Chubb, L. Alexander and J.A. Montgomery, Comparison of the toxicity and metabolism of 9-β-D-Arabinofuranosyl-2-fluoroadenine and 9-β-D-Arabinofuranosyladenine in human lymphoblastoid cells, Cancer Research 40 (1980), 2349-2355.
74. V. Ralevic and G. Burnstock, Receptors for purines and pyrimidines, Pharmacolgical Reviews 50 (1998), 413-492.
75. E. Rapaport, M.A. Garcia-Blanco and P.C. Zamecnik, Regulation of DNA replication in S phase nuclei by ATP and ADP pools, Proceedings of the National Academy of Science 76 (1979), 1643-1647.
76. E. Rapaport, Compartmentalized ATP pools produced from adenosine are nuclear pools, Journal of Cellular Physiology 105 (1980), 267-274.
77. E. Rapaport, Treatment of human tumour cells with ADP or ATP yields arrest of growth in the S-phase of the cell cycle, Journal of Cellular Physiology 114 (1983), 279-283.
78. E. Rapaport and J. Fontaine, Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools, Proceedings of the National Academy of Science USA 86 (1989), 1662-1666.
79. 2A receptor antagonists as new agents for the treatment of Parkinson's disease, Trends in Pharmacological Sciences 18 (1997), 338-345.
80. S. Rounds, W.L. Yee, D.D. Dawicki, E. Harrington, N. Parks and M.V. Cutaia, Mechanisms of extracellular ATP-and adenosine-induced apoptosis of cultured pulmonary artery endothelial cells, Americal Journal of Physiology 275 (1998), L379-L388.
81. R. Rubio, R.M. Berne, E.I. Bockman and R.R. Curnish, Relationship between adenosine concentration and oxygen supply in rat brain, American Journal of Physiology 228 (1975), 1896-1902.
82. S.M. Schrier, E.W. van Tilburg, H. van der Meulen, A.P. IJzerman, G.J. Mulder and J.F. Nagelkerke, Extracellular adenosine-induced apoptosis in mouse neuroblastoma cells studies on involvement of adenosine receptors and adenosine uptake, Biochemical Pharmacology 61 (2001), 417-425.
83. D.J. Schrier and K.M. Imre, The effects of adenosine agonists on human neutrophil function, Journal of Immunology 137 (1986), 3284-3289.
84. S.M. Schrier, B.I. Florea, G.J. Mulder, J.F. Nagelkerke and A.P. IJzerman, Apoptosis induced by extracellular ATP in the mouse neuroblastoma cell line N1E-115: studies on involvement of P2 receptors and adenosine, Biochemical Pharmacology 63 (2002), 1119-1126.
85. S.P. Seetulsingh-Goorah and B.W. Stewart, Growth inhibition of HL-60 cells by extracellular ATP: concentration-dependent involvement of a P2 receptor and adenosine generation, Biochemical Biophysical Research Communications 250 (1998), 390-396.
86. S.P. Seetulsingh-Goorah and B.W. Stewart, Growth inhibition of HL-60 cells by extracellular ATP and adenosine: Role of pyrimidine starvation and implications regarding ATP analogues as preferred antileukaemic agents, Cancer Forum 21 (1997), 84.
87. J.R. Seibold, Scleroderma, in: Kelley's Textbook of Rheumatology, (Vol. 2), S. Ruddy, E.D. Harris and C.B. Sledge, eds, WB Saunders, Philadelphia, 2000, pp. 1211-1239.
88. S. Seto, J. Carrera, M. Kubota, D.B. Wasson and D.A. Carson, Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to non-dividing human lymphocytes, Journal of Clinical Investigation 75 (1985), 377-383.
89. P. Sharma, R.D. Senthilkumar, V. Brahmachari, E. Sundaramoorthy, A. Mahajan, A. Sharma and S. Sengupta, Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine-related genes for genetic and epigenetic studies, Lipids in Health and Disease 5 (2006), 1. - BioMed Central- Open Access.
90. F.F. Snyder and J.E. Seegmiller, The adenosine-like effect of exogenous cyclic AMP upon nucleotide and PP-Ribose-P concentrations of cultured human lymphoblasts, FEBS Letters 66 (1976), 102-106.
91. M. Slater, J.A. Barden and C.R. Murphy, Distributional changes of purinergic receptor subtypes (P2X 1-7) in uterine epithelial cells during early pregnancy, Histochemical Journal 32 (2000), 365-372.
92. M. Slater, J.A. Barden and C.R. Murphy, The purinergic calcium channels P2X1,2,5,7 are down-regulated while P2X3, 4, 6 are up-regulated during apoptosis in the ageing rat prostate, Histochemical Journal 32 (2000), 571-580.
93. 2+-mediated mechanisms, Biochemical Journal 304 (1994), 877-885.
94. Y.K. Tanaka, K. Yoshihara, M. Tsuyuki and T. Kamiya, Apoptosis induced by adenosine in human leukaemia HL-60 cells, Experimental Cell Research 213 (1994), 242-252.
95. S.L. Tilley, V.A. Wagoner, C.A. Salvatore, M.A. Jacobson and B.H. Koller, 2000. Adenosine and inosine increase cutaneous vasopermeability by activating A3 receptors on mast cells, Journal of Clinical Investigation 105 (2000), 361-367.
96. O.V. Vitolo, M.T. Ciotti, C. Galli, T. Borsello and P. Calissano, Adenosine and ADP prevent apoptosis in cultured rat cerebellar granule cells, Brain Research 809 (1998), 297-301.
97. B. Wagenknecht and M. Lieberman, Adenine nucleotide degradation in cultured chick heart muscle cells, Molecular and Cellular Biochemistry 107 (1991), 119-125.
98. M.X. Wang, L.M. Ren and B.E. Shan, Inhibitory effects of extracellular adenosine triphosphate on growth of esophageal carcinoma cells, World Journal of Gastroenterology 11 (2005), 5915-5919.
99. A.R. Wakade, D.A. Przywara, K.C. Palmer, J.S. Kulkarni and T.D. Wakade, Deoxynucleoside induces neuronal apoptosis independent of neutrophic factors, Journal of Biological Chemistry 270 (1995), 17986-17992.
100. A.R. Wakade, T.D. Wakade and J.S. Kulkarni, Adenosine protects chick embryonic sympathetic neurons from apoptotic death by 2′-deoxyadenosine - importance of ATP in apoptosis, Neuroscience Letters 252 (1998), 63-166.
101. A. Wakai, J.H. Wang, D.C. Winter, J.T. Street, R.G. O'Sullivan and H.P. Redmond, Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation, Shock 15 (2001), 297-301.
102. H. Watanabe, W. Kuhne, P. Schwartz and H.M. Piper, A2-adenosine receptor stimulation increases macromolecule permeability of coronary endothelial cells. American Journal of Physiology 262 (1992), H1174-H1181.
103. G.A. Weisman, K.D. Lustig, E. Lane, N.N. Huang, I. Belzer and I. Friedberg, Growth inhibition of transformed mouse fibroblasts by adenine nucleotides occurs via generation of extracellular adenosine, Journal of Biological Chemistry 263 (1988), 12367-12372.
104. L.T. Wen and A.F. Knowles, Extracellular ATP and adenosine induce cell apoptosis of human hepatoma Li-7A cells via the A3 adenosine receptor, British Journal of Pharmacology 140 (2003), 1009-1018.
105. C.J.V.D. Wiele, J.G. Vaughn, M.R. Blackburn, C.A. Ledent, M. Jacobson, H. Jiang and L.F. Thompson, Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation, Journal of Clinical Investigation 110 (2002), 395-402.
106. H.S. Wiendl, C. Schneider and A. Ogilvie, Nucleotide metabolizing ectoenzymes are upregulated in A431 cells periodically treated with cytostatic ATP leading to partial resistance without preventing apoptosis, Biochimica Biophysica Acta 230 (1998), 282-298.
107. H.L. Wiener and G.P. Thalody, Kinetic characterization of adenosine A2 receptor-mediated relaxation in isolated rabbit aorta, European Journal of Pharmacology 238 (1993), 65-74.
108. K.C. Xie and W. Plunkett, Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-β-D- arabinofuranosyl)adenine, Cancer Research 56 (1996), 3030-3037.
109. S. Yang, D.J. Cheek, D.P. Westfall and I.L. Buxton, Purinergic axis in cardiac blood vessels: agonist-mediated release of ATP from cardiac endothelial cells, Circulation Research 74 (1994), 401-407.